Legend Biotech is a high-growth clinical-stage company delivering 56% year-over-year revenue expansion and a risk/reward ratio above 6-to-1 to analyst consensus targets, but persistent free cash flow burn, three earnings misses in the past four quarters, and quality metrics that fall well below investment-grade thresholds make this a speculative setup requiring careful position sizing.
Thesis pillars
- Cash Burn Quality Deficit→Stable
- Hypergrowth Revenue Trajectory→Stable
- Favorable Risk Reward Geometry→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Legend Biotech Corporation (LEGN) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $21.48, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Earnings in 5 days (event risk).
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is... Read more
Hold if already holding. Not a fresh buy at $21.48, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 64. Mixed signals. Hold existing position. Score 6.4/10, moderate confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: speculative.
Recent developments
updated Oct 27, 2026Recent Developments — Legend Biotech Corporation
Latest news
- NEWS Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results — fiscal.ai Oct 27, 2026 neutral
- NEWS Legend Biotech Says FDA Cleared In Vivo CAR-T Therapy LB2501 For U.S. Phase 1/2 Trial In B-Cell Cancers — benzinga Oct 15, 2026 positive
- NEWS Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68 — benzinga Oct 13, 2026 negative
- NEWS JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33 — benzinga Oct 9, 2026 neutral
- NEWS RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56 — benzinga Oct 8, 2026 positive
Latest item Oct 27, 2026 · Generated 2026-11-04T11:34:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $21.48, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 64. Mixed signals. Hold existing position. Analyst target $39.69 (+84.8%), stop $19.98 (−7.5%), A.R:R 5.7:1. Score 6.4/10, moderate confidence.
Analyst target: $39.69 (+84.8% upside). Analyst target $39.69 (+84.8%), stop $19.98 (−7.5%), A.R:R 5.7:1. Stop-loss: $19.98.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Earnings in 5 days (event risk); Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).
Legend Biotech Corporation trades at a P/E of N/A (forward 20.5). TrendMatrix value score: 8.3/10. Verdict: Hold.
22 analysts rate LEGN, with a consensus score of 4.0/5. 13 analysts publish price targets averaging $46.
What does Legend Biotech Corporation do?Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops,...
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.